Impact on patients
Session 5: Different reimbursement strategies of anti-CGRP monoclonal antibodies in Nordic countries – a clinical or political decision?
Elena Ruiz de la Torre
Executive Director, Past President, European Migraine and Headache Alliance EMHA, Belgium
Previous
Discrepancy between the recommendations and reimbursement regulations of the anti-CGRPs in the Nordics
Next
